The EU-US trade deal may cost the pharmaceutical industry $13-19 billion due to a 15% tariff on branded medicines. The EU accounts for 60% of all US pharmaceutical imports. Analysts warn of potential price hikes for consumers. The deal excludes some generic drugs from tariffs, with uncertainty on additional tariffs.

While some analysts believe protective measures for EU pharma exports may be included in the trade deal, others caution that uncertainties remain until the deal is finalized. Levies could add $13 billion to industry expenses and impact consumers. Companies like Sanofi and Roche are taking measures to mitigate potential disruptions from tariffs.

Analysts estimate that industry expenses could increase by $13-19 billion, with companies implementing strategies like stockpiling and new deals to absorb costs. It is unclear which generic drugs are exempt from duties under the deal. Shares of Sanofi, Roche, and Sandoz Group closed up between 0.5% and 1% on Monday.

Read more at Yahoo Finance: EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say